Skip to main content
. 2020 Apr 1;113(1):80–87. doi: 10.1093/jnci/djaa047

Figure 2.

Figure 2.

Uveal melanoma (UM) clinical characteristics in an MBD4-deficient (MBD4def) context. A) Age of UM onset of MBD4def patients (n = 8) in the germline consecutive UM series compared with disomy 3 (D3, n = 117) and monosomy 3 (M3, n = 198) MBD4-proficient (MBD4pro) UMs. Wilcoxon test, 1-sided (testing early UM onset in MBD4def patients): MBD4def vs M3: P = .22, MBD4def vs D3: P = .42; no age difference found between D3 and M3 groups, Wilcoxon test, 2-sided P = .087; – not shown). B and C) Metastasis-free survival (MFS, B) and overall survival (OS, C) of MBD4def UM patients (n = 8) and MBD4pro UM patients with M3 or D3. Time zero refers to time at primary UM diagnosis. MFS was defined as the interval between the date of primary UM diagnosis and the date of distant metastasis (first imaging) or death from any cause. The number of patients in each group at each time point (year) is indicated. Survival distributions were estimated by the Kaplan-Meier method and compared using the log-rank test: log-rank test, 2-sided, M3 vs D3: P = 1.98 × 10–9 (OS), P = 1.11 × 10–16 (MFS); M3 vs MBD4def: P = .11 (OS), P = .06 (MFS); D3 vs MBD4def: P = .62 (OS), P = .10 (MFS).